Journal
EUROPEAN NEUROPSYCHOPHARMACOLOGY
Volume 19, Issue 2, Pages 138-146Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.euroneuro.2008.10.002
Keywords
Dopamine D-1 receptors; Adrenergic receptors; Parkinson's disease; Enantiomeric drugs; Intrinsic activity; Locomotor activity
Funding
- Showalter Trust Fund Award
- VJW
- Purdue University
- NIMH [MH060397, MH42705]
- NIMH PDSP program
Ask authors/readers for more resources
Parkinson's disease is a neurodegenerative condition involving the death of dopaminergic neurons in the substantia nigra. Dopamine D-1 receptor agonists are potential alternative treatments to current therapies that employ L-DOPA, a dopamine precursor. We evaluated the pharmacological profiles of the enantiomers of a novel dopamine D-1 receptor full agonist, doxanthrine (DOX) at D-1 and (alpha(2C) adrenergic receptors. (+)-DOX displayed greater potency and intrinsic activity than (-)-DOX in porcine striatal tissue and in a heterologous D-1 receptor expression system. Studies in MCF7 cells, which express an endogenous human dopamine D-1-like receptor, revealed that (-)-DOX was a weak partial agonist/antagonist that reduced the functional activity of (+)-DOX and dopamine. (-)-DOX had 10-fold greater potency than (+)-DOX at alpha(2C) adrenergic receptors, with an EC50 value of 4 nM. These findings demonstrate a reversed stereoselectivity for the enantiomers of DOX at D-1 and alpha(2C) receptors and have implications for the therapeutic utility of doxanthrine. (C) 2008 Elsevier B.V. and ECNP. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available